Welcome to the Research Digest’s 84th edition. This month we recap research studies of ME/CFS endothelial cell dysfunction and how metabolomics may provide insight into ME/CFS, pre-and post-exercise. Also presented, is advice for the treatment of Long Covid patients, given the injustices experienced by those with ME/CFS and a very honest account of what lengths a person living with ME/CFS will go to, in the absence of ME/CFS treatments; accenting the dire need for vital ME/CFS research funding. Read more
You can also join our community and choose to have the Research Digest delivered straight to your inbox every month on a Friday afternoon by signing up to our mailing list here.
We appreciate the support of everyone who reads the Research Digest – we encourage regular subscribers to support us with a suggested donation of $2. You can donate here.
Welcome to the 83rd edition of the Research Digest. This month’s edition features ME/CFS studies focused on orthostatic intolerance, the effects of Naltrexone on ME/CFS NK cells, as well as a promising ME/CFS eye movement diagnostic tool. This edition also highlights Emerge Australia’s radio interviews featuring Anne Wilson, our CEO campaigning for an update to the ME/CFS guidelines and Richard Schloeffel (our Medical Director) calling out the disbelief of ME/CFS as “Medical Abuse Syndrome”. Read more
Welcome to the 82nd edition of the Research Digest. This month’s edition features studies investigating blood flow abnormalities that may contribute to the pathogenesis of ME/CFS and how lessons learnt from heat stroke may be useful to better understand ME/CFS. Further analysis of Long Covid and its overlap with ME/CFS symptomology is also presented with future research areas postulated. And last but not least, we present highlights from Anne Wilson’s recent radio interview on ABC Life Matters, Read more
Welcome to the 81st edition of the Research Digest. This edition reviews research articles investigating the potential of the cortical autonomic network, to act as a therapeutic target for ME/CFS symptom management, the involvement of C1q in ME/CFS pathology and more evidence demonstrating a linkage between ME/CFS and Long Covid. The highlights from a radio interview featuring Emerge Australia’s CEO Anne Wilson on 2GB, are also presented. Read more
Welcome to the 80th edition of the Research Digest. This edition summarises research papers trialling CT38s to investigate the involvement of the corticotropin-releasing factor system in ME/CFS and an Australian study observing the impact of life stressors, on those living with ME/CFS. The 80th and final edition of the research digest is concluded for 2021, with Emerge Australia’s full-page advertisement in the AFR, providing ME/CFS a voice in the national Long COVID conversation. Read more
Welcome to the 79th edition of the Research Digest. This month’s edition of the research digest presents an article distinguishing ME/CFS patients based upon herpesviruses serology and also a comprehensive examination of severely ill ME/CFS patients. The 79th edition also highlights a review paper discussing redox imbalance and how this contributes to biological abnormalities that have long been known for ME/CFS, but now are also being observed in patients with acute and Long COVID. Read more
Welcome to the 78th edition of the Research Digest. This edition of the research digest features articles investigating ACE2 gene expression in ME/CFS blood cells and findings from a UK audit of doctors knowledge and experience with ME/CFS. This edition also highlights recent reports in the media, articulating links between long-COVID and ME/CFS. Read more
Welcome to the 77th edition of the Research Digest. This edition of the digest presents articles exploring the feasibility of N-of-1 observational design for the study of ME/CFS, and attribution theory to investigate the relationship between higher perceived stigma and lower functional status found in ME/CFS. Read more
Welcome to the 76th edition of the Research Digest. This edition features articles describing the potential therapeutic benefit of low dose Naltrexone in ME/CFS and a pilot eLORETA study examining the central autonomic network involvement in PEM in ME/CFS. Read more